Menatetrenone Series (Vitamin K2)
Functions of Vitamin K2
1. Curing and preventing osteoporosis: VK2 produces a specific protein known as osteocalcin which can bind calcium, therefore to increase the density of bones and to prevent fracture.
2. Curing haemorrhage caused by VK2 deficiency: It promotes the formation of thrombin, accelerates blood clotting, maintains proper clotting time; and also used as quick coagulant in surgeries or first aids.
3. Function of diuresis, promoting the detoxifcation of liver and lowering blood pressure.
4. VK2 is a PKA active regulator used for preventing and treating hepatic disease. And it can be used for treating liver cancer and lung cancer.
Vitamin K2’s effects on osteoporosis
Vitamin K2 is a cofactor of gamma-carboxylase, which converts the glutamic acid (Glu) residue in steocalcin molecules to gamma-carboxyglutamic acid (Gla), and is, therefore, essential for gamma-carboxylation of osteocalcin. Vitamin K2 also enhances osteocalcin accumulation in the extracellular matrix of osteoblasts in vitro. Osteocalcin-knockout mice develop hyperostosis, suggesting that the Gla-containing osteocalcin promotes normal bone mineralization, and it probably regulates the growth of hydroxyapatite crystals. Vitamin K2 also inhibits the expression of the osteoclast differentiation factor (ODF)/RANK ligand, tartrate-resistant acid phosphatase activity, and mononuclear cell formation, and induces osteoclast apoptosis in vitro.
Furthermore, bone pectin is formed by osteocalcin produced with vitamin K2 and protein, and calcium, then caccumulates in bone. So vitamin K2, calcium and protein are three factors which are essential to increase bone density. There is some evidence indicating that vitamin K2 prevents bone resorption in ovariectomized rats, retards the increase in bone turnover in orchidectomized rats, ameliorates the increase in bone resorption and decrease in bone formation in sciatic neurectomized rats, and prevents the decrease in bone formation in glucocorticoid-treated rats. These findings suggest that vitamin K2 may not only stimulate bone formation but also suppress bone resorption in vivo. Clinically, vitamin K2 sustains the lumbar bone mineral density (BMD) and prevents osteoporotic fractures in patients with age-related osteoporosis, prevents vertebral fractures in patients with glucocorticoid-induced osteoporosis, increases the metacarpal BMD in the paralytic upper extremities of patients with cerebrovascular disease, and sustains the lumbar BMD in patients with liver-dysfunction-induced osteoporosis.
Forms- Vitamin K2(20) (MK-4) Menaquinon-4 Capsules and Tablets
- Vitamin K2(35) (MK-7) Menaquinon-7 Capsules and Tablets
- Vitamin K2(45) (MK-9) Menaquinon-9 Capsules and Tablets
- 1. Vitamin K2(20) (MK-4) Menaquinon-4
- Product Code: 185834
-
Code | Specification | MOQ |
0.13% Oil |
5-100 Kg |
|
0.13% Powder (sustained release preparation) |
10 Kg |
|
1.3% Oil |
1-5 Kg |
|
1.3% Powder (sustained release preparation) |
1 Kg |
|
98.0% Powder (Equivalent to JP14) |
1 Kg |
|
98.0% Oil (JP14) |
1 Kg |
Alternative Names: Vitamin K2, menaquinone, menaquinon-4, menatetrenone, menatetren, menatetrenona, menatetrenonum, MK-4, E3100; 2-methyl-3-[(2'E,6'E,10'E)-3',7',11',15'- tetramethylhexadeca-2',6',10',14'- tetraen-1'-yl]-1,4-naphthalenedione
CAS Code: [863-61-6] or [11032-49-8]
Molecular Formula: C31H40O2
Molecular Weight: 444.65
Shelf life: 2 years
Hazard Class: Non-hazardous
2. Vitamin K2(35) (MK-7) Menaquinon-7
Product Code: 185837
Code | Specification | MOQ |
1.0% on DCP (Pharm. excipient CaHPO4) |
5 Kg |
|
0.5% on DCP (Pharm. excipient CaHPO4) |
5 Kg |
|
0.13% Oil |
5-100 Kg |
|
0.13% Powder (sustained release preparation) |
10 Kg |
|
1.3% Oil |
1-5 Kg |
|
1.3% Powder (sustained release preparation) |
1 Kg |
Alternative Names: Menaquinon-7; MK-7; (all-E)-2-(3,7,11,15,19,23,27-Heptamethyl -2,6,10,14,18,22,26-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione ;
CAS Code: [27670-94-6]
Molecular Formula: C46H64O2
Molecular Weight: 649.0
Shelf life: 2 years
Hazard Class: Safe
3. Vitamin K2(45)(MK-9) Menaquinon-9
Product Code: 185838
Code | Specification | MOQ |
98% Powder |
1 Kg |
Alternative Names: Menaquinon-9; MK-9 ; (all-E)-2-(3,7,11,15,19,23,27,31,35-Heptamethyl- 2,6,10,14,18,22,26,30,34-octacosaheptaenyl)-3-methyl-1,4-naphthalenedione ;
CAS Code: [523-39-7]
Molecular Formula: C56H80O2
Molecular Weight: 784.0
Shelf life: 2 years
Hazard Class: Non-hazardous
![]() |
![]() |
![]() |
官網(wǎng):www.baichuan365.com | 微信服務(wù)號(hào):iseebio | 微博:seebiobiotech |
![]() |
![]() |
![]() |
商城:mall.seebio.cn | 微信訂閱號(hào):seebiotech | 泉養(yǎng)堂:www.canmedo.com |
相關(guān)資訊
- 麥芽酚和乙基麥芽酚
- 科研用細(xì)胞因子,趨化因子和相關(guān)因子Elisa試劑盒
- seebio品牌自主產(chǎn)品2017年文獻(xiàn)引用(一)
- 基因影響大學(xué)成績(jī)
- Seebio 優(yōu)質(zhì)試劑全新上市之酶與酶作用底物系列
- Cancer Cell:科學(xué)家發(fā)現(xiàn)能抑制多種腫瘤的酶抑制劑
- 中科院上海營(yíng)養(yǎng)與健康研究所專家團(tuán)隊(duì)蒞臨西寶生物考察
- 研究發(fā)現(xiàn)細(xì)胞命運(yùn)調(diào)控的“表觀組-代謝組-表觀組”跨界蝴蝶效應(yīng)
- Lancet Neurol:科學(xué)家有望開發(fā)出首個(gè)治療阿爾茲海默病的疫苗
- 2013年圣誕晚會(huì)
新進(jìn)產(chǎn)品
同類文章排行
- 膽堿酯酶檢測(cè)原料一覽
- 猴痘病毒檢測(cè)原料(涵蓋診斷酶、抗原、抗體),西寶生物助力猴痘檢測(cè)
- 西寶生物CHO細(xì)胞、HEK293細(xì)胞、 Vero細(xì)胞培養(yǎng)基產(chǎn)品
- 人和動(dòng)物免疫球蛋白IgG全新上市
- 如何選擇合適的表面活性劑?
- 尿液分析試紙檢測(cè)原理及產(chǎn)品推薦
- 總膽紅素/直接膽紅素檢測(cè)一站式解決方案
- 分子診斷用酶原料一站式服務(wù)盡在西寶生物
- 體外診斷中交聯(lián)劑的用途與選擇
- 優(yōu)異的化妝品級(jí)水溶性β-1,3-葡聚糖
資訊文章
您的瀏覽歷史
